Weinblatt ME, et al. - This study was performed to assess mavrilimumab (anti–granulocyte-macrophage colony-stimulating factor [GM-CSFR]-α monoclonal antibody) and golimumab (anti-tumor necrosis factor [TNF] monoclonal antibody) in patients with rheumatoid arthritis (RA), with inadequate responses to disease-modifying antirheumatic drugs (DMARD-IR) and/or anti-TNF agents (anti-TNF-IR). In this study, mavrilimumab 100 mg every other week (eow) and golimumab 50 mg Q4W, showed clinical viability and were well-tolerated forDMARD-IR and anti–TNF-IR RA patients.